Background: Oral polio vaccine (OPV) may improve resistance to non-polio-infections. We tested whether OPV reduced the risk of illness and mortality before coronavirus disease 2019 (COVID-19) vaccines were available. Methods: During the early COVID-19 pandemic, houses in urban Guinea-Bissau were randomized 1:1 to intervention or control. Residents aged 50+ years were invited to participate. Participants received bivalent OPV (single dose) or nothing. Rates of mortality, admissions, and consultation for infections (primary composite outcome) during 6 months of follow-up were compared in Cox proportional hazards models adjusted for age and residential area. Secondary outcomes included mortality, admissions, consultations, and symptoms of infection. Results: We followed 3726 participants (OPV, 1580; control, 2146) and registered 66 deaths, 97 admissions, and 298 consultations for infections. OPV did not reduce the risk of the composite outcome overall (hazard ratio [HR] = 0.97; 95% confidence interval [CI], .79-1.18). OPV reduced the risk in males (HR = 0.71; 95% CI, .51-.98) but not in females (HR = 1.18; 95% CI, .91-1.52) (P for same effect = .02). OPV also reduced the risk in Bacillus Calmette-Guérin scar-positive (HR = 0.70; 95% CI, .49-.99) but not in scar-negative participants (HR = 1.13; 95% CI, .89-1.45) (P = .03). OPV had no overall significant effect on mortality (HR = 0.96; 95% CI, .59-1.55), admissions (HR = 0.76; 95% CI, .49-1.17) or recorded consultations (HR = 0.99; 95% CI, .79-1.25), but the OPV group reported more episodes with symptoms of infection (6050 episodes; HR = 1.10 [95% CI, 1.03-1.17]). Conclusions: In line with previous studies, OPV had beneficial nonspecific effects in males.
Background: Oral polio vaccine (OPV) may improve resistance to non-polio-infections. We tested whether OPV reduced the risk of illness and mortality before coronavirus disease 2019 (COVID-19) vaccines were available. Methods: During the early COVID-19 pandemic, houses in urban Guinea-Bissau were randomized 1:1 to intervention or control. Residents aged 50+ years were invited to participate. Participants received bivalent OPV (single dose) or nothing. Rates of mortality, admissions, and consultation for infections (primary composite outcome) during 6 months of follow-up were compared in Cox proportional hazards models adjusted for age and residential area. Secondary outcomes included mortality, admissions, consultations, and symptoms of infection. Results: We followed 3726 participants (OPV, 1580; control, 2146) and registered 66 deaths, 97 admissions, and 298 consultations for infections. OPV did not reduce the risk of the composite outcome overall (hazard ratio [HR] = 0.97; 95% confidence interval [CI], .79-1.18). OPV reduced the risk in males (HR = 0.71; 95% CI, .51-.98) but not in females (HR = 1.18; 95% CI, .91-1.52) (P for same effect = .02). OPV also reduced the risk in Bacillus Calmette-Guérin scar-positive (HR = 0.70; 95% CI, .49-.99) but not in scar-negative participants (HR = 1.13; 95% CI, .89-1.45) (P = .03). OPV had no overall significant effect on mortality (HR = 0.96; 95% CI, .59-1.55), admissions (HR = 0.76; 95% CI, .49-1.17) or recorded consultations (HR = 0.99; 95% CI, .79-1.25), but the OPV group reported more episodes with symptoms of infection (6050 episodes; HR = 1.10 [95% CI, 1.03-1.17]). Conclusions: In line with previous studies, OPV had beneficial nonspecific effects in males.
Authors: Paul Welaga; Abraham Oduro; Cornelius Debpuur; Peter Aaby; Henrik Ravn; Andreas Andersen; Fred Binka; Abraham Hodgson Journal: Vaccine Date: 2017-03-22 Impact factor: 3.641
Authors: Nadezhda V Yagovkina; Lev M Zheleznov; Ksenia A Subbotina; Andrey A Tsaan; Liubov I Kozlovskaya; Ilya V Gordeychuk; Anastasia K Korduban; Yury Y Ivin; Anastasia A Kovpak; Anastasia N Piniaeva; Anna A Shishova; Elena Y Shustova; Yusuf K Khapchaev; Galina G Karganova; Alexandra A Siniugina; Tatiana V Pomaskina; Aleksandr A Erovichenkov; Konstantin Chumakov; Aydar A Ishmukhametov Journal: Front Immunol Date: 2022-05-30 Impact factor: 8.786
Authors: Andreas Rieckmann; Marie Villumsen; Signe Sørup; Line Klingen Haugaard; Henrik Ravn; Adam Roth; Jennifer Lyn Baker; Christine Stabell Benn; Peter Aaby Journal: Int J Epidemiol Date: 2017-04-01 Impact factor: 7.196
Authors: C S Benn; A Salinha; S Mendes; C Cabral; C Martins; S Nielsen; A B Fisker; F Schaltz-Buchholzer; C S Jørgensen; P Aaby Journal: Public Health Date: 2021-12-03 Impact factor: 2.427
Authors: Farrokh Habibzadeh; Konstantin Chumakov; Mohammad M Sajadi; Mahboobeh Yadollahie; Kristen Stafford; Ashraf Simi; Shyamasundaran Kottilil; Iman Hafizi-Rastani; Robert C Gallo Journal: PLoS One Date: 2022-03-17 Impact factor: 3.240
Authors: Lisa Lundberg; Maria Bygdell; Gustaf Stukat von Feilitzen; Susanne Woxenius; Claes Ohlsson; Jenny M Kindblom; Susannah Leach Journal: Vaccine Date: 2021-06-22 Impact factor: 4.169
Authors: Signe Sørup; Lone G Stensballe; Tyra G Krause; Peter Aaby; Christine S Benn; Henrik Ravn Journal: Open Forum Infect Dis Date: 2015-12-17 Impact factor: 3.835